|
|
||||||||
|
|
|||||||||
|
|
Oncology-Basic Science: Therapy, Metrics & InterventionTherapy, Metrics & Intervention Posters |
1 Radiology, University of Massachusetts Medical School, Worcester, Massachusetts
1408
Objectives: This laboratory has used phage display to identify novel peptides with binding affinity for TAG-72. We have now synthesized the most promising peptide, GGVSCMQTSPVCENNL (A2-6), and evaluated its properties in vitro and in vivo in tumored mice.
Methods: The peptide was both radiolabeled with 99mTc and biotinylated. The radiolabeled peptide was used to confirm serum stability and to estabish its distribution and clearance in tumor-bearing mice while the biotinylated peptide was used for histology. Both were used to confirm TAG-72 binding specificity.
Results: RP and SE HPLC demonstrated stability of the 99mTc labeled peptide in 37oC human serum through 2 h. By flow cytometry, binding of the biotinylated peptide to TAG-72 positive LS174T cells was shown to be concentration dependent as expected for specific binding and with only background binding to control TAG-72 negative HT-29 cells. Specificity of binding was also demonstrated with the 99mTc labeled peptide that showed inhibited binding to LS174T cells with increasing concentrations of unlabeled peptide. Immnuohistochemical staining of LS-174T tumor xenograph sections for the biotinylated A2-6 peptide was similar to that for the TAG-72 positive B72.3 antibody. The 99mTc-A2-6 biodistribution in LS-174T tumored mice showed rapidly decreasing blood levels with evidence of hepatobilliary clearance and with a tumor to normal leg ratio reaching a maximum of 2.6 at 30 min. Tumor accumulation was reduced 6-fold with pre administration of excess unlabeled peptide.
Conclusions: When isolated from its phage, the A2-6 peptide shows favorable specificity of binding and tumor accumulation to be considered further as a potential imaging agent for TAG-72 positive cancers.
| ||||||||||||||||||||||||||||||||||||||